The multikinase inhibitor regorafenib decreases angiogenesis and improves portal hypertension

BACKGROUND AND AIMS: Angiogenesis is critically involved in the development of liver fibrosis, portal hypertension (PHT) and hepatocellular carcinoma (HCC). Regorafenib is a novel second-line therapy for HCC, but might also be beneficial in fibrosis and PHT even in absence of HCC. This study investi...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Oncotarget
Main Authors: Uschner, Frank Erhard, Schueller, Florian, Nikolova, Ivelina, Klein, Sabine, Schierwagen, Robert, Magdaleno, Fernando, Gröschl, Stefanie, Loosen, Sven, Ritz, Thomas, Roderburg, Christoph, Vucur, Michael, Kristiansen, Glen, Lammers, Twan, Luedde, Tom, Trebicka, Jonel
Format: Artigo
Sprog:Inglês
Udgivet: Impact Journals LLC 2018
Fag:
Research Paper
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6281422/
https://ncbi.nlm.nih.gov/pubmed/30546838
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.26333
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker